---
title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -1.31"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251895917.md"
datetime: "2025-08-06T20:15:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251895917.md)
  - [en](https://longbridge.com/en/news/251895917.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251895917.md)
generator: "portal-rs"
---

# REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -1.31

EPS: As of FY2025 Q2, the actual value is USD -1.31.

EBIT: As of FY2025 Q2, the actual value is USD -247.79 M.

### Segment Revenue

-   **Research and Development Expenses**: $224.1 million for the three months ended June 30, 2025, compared to $134.9 million for the same period in 2024, representing a 66% increase. For the six months ended June 30, 2025, expenses were $429.9 million, compared to $252.9 million in 2024, a 70% increase.

### Operational Metrics

-   **Net Loss**: $247.8 million for the three months ended June 30, 2025, compared to $133.2 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $461.2 million, compared to $249.2 million in 2024.
-   **General and Administrative Expenses**: $40.6 million for the three months ended June 30, 2025, compared to $21.7 million for the same period in 2024, an 87% increase. For the six months ended June 30, 2025, expenses were $75.6 million, compared to $44.5 million in 2024, a 70% increase.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $416.2 million for the six months ended June 30, 2025, compared to - $288.7 million for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $18.3 million for the six months ended June 30, 2025, compared to - $140.0 million used in 2024.
-   **Net Cash Provided by Financing Activities**: $257.5 million for the six months ended June 30, 2025, compared to $8.3 million in 2024.

### Unique Metrics

-   **Liability Related to the Sale of Future Royalties**: $245.1 million as of June 30, 2025, resulting from a $250.0 million upfront payment received under the Royalty Purchase Agreement.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue advancing its RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, through clinical development. It expects to initiate several pivotal trials in 2025 and 2026, including a global, randomized Phase 3 study of daraxonrasib in first-line metastatic PDAC and a monotherapy study as adjuvant treatment for resectable PDAC.
-   **Non-Core Business**: The company is exploring various strategic collaborations, including with Tango Therapeutics and Summit Therapeutics, to evaluate combination therapies involving its RAS(ON) inhibitors.

### Related Stocks

- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Why Dell's Blowout Q2 Gives Investors No Reason to Stay on the Sidelines](https://longbridge.com/en/news/297913696.md)
- [BUZZ-Street View: Broadcom's pipeline soothes AI spending doubts](https://longbridge.com/en/news/297905938.md)
- [SpaceX Was ‘Nowhere’ in AI 6 Months Ago — Now It’s an Anthropic Rival After the $60 Billion Cursor Deal, Says Oppenheimer](https://longbridge.com/en/news/297900623.md)
- [PATH: Q2 revenue up 13% year-over-year, with robust margins and new AI-driven product launches](https://longbridge.com/en/news/297953966.md)
- [Lululemon cuts annual revenue, profit forecast](https://longbridge.com/en/news/297953201.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**